CYMD201

CYMD201 is an investigational cell and gene therapy being developed by FibroGenesis for the treatment of muscular dystrophy. The therapy is built upon a human dermal fibroblast (HDF) platform and employs a novel mechanism of action that combines cell therapy with gene transfer techniques. Specifically, CYMD201 utilizes cell fusion and horizontal gene transfer to deliver the dystrophin gene or protein to muscle cells, aiming to restore the expression of dystrophin which is deficient in patients with muscular dystrophy. By replenishing this critical structural protein, the therapy seeks to improve muscle fiber integrity and overall muscle function. CYMD201 is currently in the preclinical stage of development.